Nature Cancer

Article	Citations
Cancer vaccines: the next immunotherapy frontier	344
Overcoming therapy resistance in EGFR-mutant lung cancer	245
Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression	237
Cancer-associated fibroblasts in the single-cell era	225
Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer	203
A first-in-class polymerase theta inhibitor selectively targets homologous-recombination-deficient tumors	202
Pathway-based classification of glioblastoma uncovers a mitochondrial subtype with therapeutic vulnerabilities	197
Molecular pathogenesis and systemic therapies for hepatocellular carcinoma	191
Cell type and gene expression deconvolution with BayesPrism enables Bayesian integrative analysis across bulk and single-cell RNA sequencing in oncology	186
Fatty acid synthesis is required for breast cancer brain metastasis	186
Artificial intelligence in histopathology: enhancing cancer research and clinical oncology	178
A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology	178
Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity	178
Gradient of Developmental and Injury Response transcriptional states defines functional vulnerabilities underpinning glioblastoma heterogeneity	167
The metabolic landscape of RAS-driven cancers from biology to therapy	163
The cGAS–STING pathway and cancer	158
Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer	147
Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial	144
CD4+ T cells in cancer	138
EZH2 inhibition activates a dsRNA–STING–interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer	135
Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas	134
A tumor-derived type III collagen-rich ECM niche regulates tumor cell dormancy	134
Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia	132
Translational advances in pancreatic ductal adenocarcinoma therapy	130
Multimodal data integration using machine learning improves risk stratification of high-grade serous ovarian cancer	130

Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer	127
Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy	125
Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma	116
CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity	115
Single-cell meta-analyses reveal responses of tumor-reactive CXCL13+ T cells to immune-checkpoint blockade	113
The interaction of CD4+ helper T cells with dendritic cells shapes the tumor microenvironment and immune checkpoint blockade response	113
Few-shot learning creates predictive models of drug response that translate from high-throughput screens to individual patients	110
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study	109
MYCN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis	106
Three-dimensional imaging mass cytometry for highly multiplexed molecular and cellular mapping of tissues and the tumor microenvironment	104
A systematic CRISPR screen defines mutational mechanisms underpinning signatures caused by replication errors and endogenous DNA damage	104
Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity	103
Targeting public neoantigens for cancer immunotherapy	100
Melanoma-derived small extracellular vesicles induce lymphangiogenesis and metastasis through an NGFR-dependent mechanism	98
Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors	95
Emerging strategies for treating metastasis	94
Super enhancers define regulatory subtypes and cell identity in neuroblastoma	93
A single-cell atlas of glioblastoma evolution under therapy reveals cell-intrinsic and cell-extrinsic therapeutic targets	93
Dual-targeting CAR-T cells with optimal co-stimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors	90
Single-cell analyses reveal YAP/TAZ as regulators of stemness and cell plasticity in glioblastoma	88
Cancer cell plasticity during tumor progression, metastasis and response to therapy	87
ENO1 suppresses cancer cell ferroptosis by degrading the mRNA of iron regulatory protein 1	82
Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy	82
The present and future of PI3K inhibitors for cancer therapy	82
Patterns of seroconversion for SARS-CoV-2 IgG in patients with malignant disease and association with anticancer therapy	81
Targeting PUS7 suppresses tRNA pseudouridylation and glioblastoma tumorigenesis	81
Dysregulation and therapeutic targeting of RNA splicing in cancer	81
An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer	80
Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia	79
ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1-mutant lung cancer	79
Bone marrow NG2+/Nestin+ mesenchymal stem cells drive DTC dormancy via TGF-β2	78
Clonal expansion of T memory stem cells determines early anti-leukemic responses and long-term CAR T cell persistence in patients	76
Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer	76
Neutrophil oxidative stress mediates obesity-associated vascular dysfunction and metastatic transmigration	75
Engineering-enhanced CAR T cells for improved cancer therapy	74
Targeting PAK4 to reprogram the vascular microenvironment and improve CAR-T immunotherapy for glioblastoma	72
Bystander T cells in cancer immunology and therapy	71
The status of tumor mutational burden and immunotherapy	70
Radiation exposure elicits a neutrophil-driven response in healthy lung tissue that enhances metastatic colonization	70
Astrocytic laminin-211 drives disseminated breast tumor cell dormancy in brain	69
Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study	68
Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets	68
Combined inhibition of Aurora-A and ATR kinases results in regression of MYCN-amplified neuroblastoma	66
Understanding and overcoming tumor heterogeneity in metastatic breast cancer treatment	65
Castration-mediated IL-8 promotes myeloid infiltration and prostate cancer progression	65
Advances in antibody-based therapy in oncology	65
The CIP2A–TOPBP1 axis safeguards chromosome stability and is a synthetic lethal target for BRCA-mutated cancer	64
Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors	64
Multifunctional barcoding with ClonMapper enables high-resolution study of clonal dynamics during tumor evolution and treatment	61
A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes	61

ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma	60
Clinical and translational advances in ovarian cancer therapy	60
Ectopic JAK–STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance	60
cfDNA methylome profiling for detection and subtyping of small cell lung cancers	60
Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study	59
Mutant Kras co-opts a proto-oncogenic enhancer network in inflammation-induced metaplastic progenitor cells to initiate pancreatic cancer	59
Autophagy inhibition by targeting PIKfyve potentiates response to immune checkpoint blockade in prostate cancer	59
The proliferative history shapes the DNA methylome of B-cell tumors and predicts clinical outcome	59
The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology	59
Selective multi-kinase inhibition sensitizes mesenchymal pancreatic cancer to immune checkpoint blockade by remodeling the tumor microenvironment	57
Mex3a marks drug-tolerant persister colorectal cancer cells that mediate relapse after chemotherapy	57
A local human Vδ1 T cell population is associated with survival in nonsmall-cell lung cancer	56
TNF-α-producing macrophages determine subtype identity and prognosis via AP1 enhancer reprogramming in pancreatic cancer	55
Proteogenomics of non-small cell lung cancer reveals molecular subtypes associated with specific therapeutic targets and immune-evasion mechanisms	54
Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia	54
GAP43-dependent mitochondria transfer from astrocytes enhances glioblastoma tumorigenicity	54
An artificial intelligence framework integrating longitudinal electronic health records with real-world data enables continuous pan-cancer prognostication	53
CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity	52
Perivascular tenascin C triggers sequential activation of macrophages and endothelial cells to generate a pro-metastatic vascular niche in the lungs	52
Compensatory CSF2-driven macrophage activation promotes adaptive resistance to CSF1R inhibition in breast-to-brain metastasis	52
KMT2C deficiency promotes small cell lung cancer metastasis through DNMT3A-mediated epigenetic reprogramming	51
The Cancer Surfaceome Atlas integrates genomic, functional and drug response data to identify actionable targets	51
Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma	51
Pharmacological inhibition of BACE1 suppresses glioblastoma growth by stimulating macrophage phagocytosis of tumor cells	51
An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance	50
Accelerating precision medicine in metastatic prostate cancer	50
A palmitate-rich metastatic niche enables metastasis growth via p65 acetylation resulting in pro-metastatic NF-κB signaling	50
ALK-positive lung cancer: a moving target	50
Multi-omic profiling of peritoneal metastases in gastric cancer identifies molecular subtypes and therapeutic vulnerabilities	50
A machine learning model for ranking candidate HLA class I neoantigens based on known neoepitopes from multiple human tumor types	49
Radiotherapy in combination with CD47 blockade elicits a macrophage-mediated abscopal effect	49
Advancing Cancer Therapy	49
The cancer-testis lncRNA lnc-CTHCC promotes hepatocellular carcinogenesis by binding hnRNP K and activating YAP1 transcription	48
Hotspot DNMT3A mutations in clonal hematopoiesis and acute myeloid leukemia sensitize cells to azacytidine via viral mimicry response	48
MACHETE identifies interferon-encompassing chromosome 9p21.3 deletions as mediators of immune evasion and metastasis	48
Targeting the bicarbonate transporter SLC4A4 overcomes immunosuppression and immunotherapy resistance in pancreatic cancer	47
Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response	47
An anti-PD-1–GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy	47
Limited nutrient availability in the tumor microenvironment renders pancreatic tumors sensitive to allosteric IDH1 inhibitors	47
APOBEC3A drives deaminase domain-independent chromosomal instability to promote pancreatic cancer metastasis	46
Moving pan-cancer studies from basic research toward the clinic	46
The clinical utility of integrative genomics in childhood cancer extends beyond targetable mutations	45
Highly aneuploid non-small cell lung cancer shows enhanced responsiveness to concurrent radiation and immune checkpoint blockade	44
High-plex immunofluorescence imaging and traditional histology of the same tissue section for discovering image-based biomarkers	43
ZFP281 drives a mesenchymal-like dormancy program in early disseminated breast cancer cells that prevents metastatic outgrowth in the lung	43
Checkpoint inhibitor immunotherapy diminishes oocyte number and quality in mice	42
Potent suppression of neuroendocrine tumors and gastrointestinal cancers by CDH17CAR T cells without toxicity to normal tissues	42
Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer	42
Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1	41
Cancer-associated fibroblasts employ NUFIP1-dependent autophagy to secrete nucleosides and support pancreatic tumor growth	41
Downregulation of the FTO m6A RNA demethylase promotes EMT-mediated progression of epithelial tumors and sensitivity to Wnt inhibitors	41
Pharmacological targeting of MTHFD2 suppresses acute myeloid leukemia by inducing thymidine depletion and replication stress	40
Epigenetic targeted therapy of stabilized BAP1 in ASXL1 gain-of-function mutated leukemia	39
Breast cancer cells survive chemotherapy by activating targetable immune-modulatory programs characterized by PD-L1 or CD80	38
Complement activation promoted by the lectin pathway mediates C3aR-dependent sarcoma progression and immunosuppression	38
Serial single-cell genomics reveals convergent subclonal evolution of resistance as patients with early-stage breast cancer progress on endocrine plus CDK4/6 therapy	38
A phase I/Ib trial and biological correlate analysis of neoadjuvant SBRT with single-dose durvalumab in HPV-unrelated locally advanced HNSCC	38
The IRENA lncRNA converts chemotherapy-polarized tumor-suppressing macrophages to tumor-promoting phenotypes in breast cancer	38
SETD2 loss perturbs the kidney cancer epigenetic landscape to promote metastasis and engenders actionable dependencies on histone chaperone complexes	37
Siglec-9 acts as an immune-checkpoint molecule on macrophages in glioblastoma, restricting T-cell priming and immunotherapy response	36
Multi-omics reveals clinically relevant proliferative drive associated with mTOR-MYC-OXPHOS activity in chronic lymphocytic leukemia	36
Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling	36
Tumor-intrinsic sensitivity to the pro-apoptotic effects of IFN-γ is a major determinant of CD4+ CAR T-cell antitumor activity	36
LILRB3 supports acute myeloid leukemia development and regulates T-cell antitumor immune responses through the TRAF2–cFLIP–NF-κB signaling axis	35
Therapeutic targeting of the mevalonate–geranylgeranyl diphosphate pathway with statins overcomes chemotherapy resistance in small cell lung cancer	35
Mesenchymal and adrenergic cell lineage states in neuroblastoma possess distinct immunogenic phenotypes	35
The challenges of implementing low-dose computed tomography for lung cancer screening in low- and middle-income countries	35
Bispecific antibodies increase the therapeutic window of CD40 agonists through selective dendritic cell targeting	35
Specific targeting of glioblastoma with an oncolytic virus expressing a cetuximab-CCL5 fusion protein via innate and adaptive immunity	35
Disrupting the phase separation of KAT8–IRF1 diminishes PD-L1 expression and promotes antitumor immunity	35
Pharmacological disruption of the MTDH–SND1 complex enhances tumor antigen presentation and synergizes with anti-PD-1 therapy in metastatic breast cancer	34
Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer	34
The landscape of T cell antigens for cancer immunotherapy	33
CD103+ regulatory T cells underlie resistance to radio-immunotherapy and impair CD8+ T cell activation in glioblastoma	33
Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders	33
Chemotherapy and mismatch repair deficiency cooperate to fuel TP53 mutagenesis and ALL relapse	32
The current landscape of immunotherapy for pediatric brain tumors	32
LXRα activation and Raf inhibition trigger lethal lipotoxicity in liver cancer	31
The immunopeptidome landscape associated with T cell infiltration, inflammation and immune editing in lung cancer	31
Single-cell analysis and functional characterization uncover the stem cell hierarchies and developmental origins of rhabdomyosarcoma	31

CD8+ T cells maintain killing of MHC-I-negative tumor cells through the NKG2D–NKG2DL axis	31
Chronic liver disease enables gut Enterococcus faecalis colonization to promote liver carcinogenesis	31
Ex vivo organotypic cultures for synergistic therapy prioritization identify patient-specific responses to combined MEK and Src inhibition in colorectal cancer	30
A single-cell map of dynamic chromatin landscapes of immune cells in renal cell carcinoma	30
Advances in ovarian cancer, from biology to treatment	30
METTL16 antagonizes MRE11-mediated DNA end resection and confers synthetic lethality to PARP inhibition in pancreatic ductal adenocarcinoma	30
LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer	29
Targeting PARP11 to avert immunosuppression and improve CAR T therapy in solid tumors	29
Integrative multi-omics networks identify PKCδ and DNA-PK as master kinases of glioblastoma subtypes and guide targeted cancer therapy	29
Phosphate dysregulation via the XPR1–KIDINS220 protein complex is a therapeutic vulnerability in ovarian cancer	29
Single-cell analyses implicate ascites in remodeling the ecosystems of primary and metastatic tumors in ovarian cancer	29
EZH2 inhibition remodels the inflammatory senescence-associated secretory phenotype to potentiate pancreatic cancer immune surveillance	29
Scribble mis-localization induces adaptive resistance to KRAS G12C inhibitors through feedback activation of MAPK signaling mediated by YAP-induced MRAS	28
Differential integrated stress response and asparagine production drive symbiosis and therapy resistance of pancreatic adenocarcinoma cells	28
Radiation-activated secretory proteins of Scgb1a1+ club cells increase the efficacy of immune checkpoint blockade in lung cancer	28
Single-cell profiling to explore pancreatic cancer heterogeneity, plasticity and response to therapy	28
Age-associated microenvironmental changes highlight the role of PDGF-C in ER+ breast cancer metastatic relapse	27
Structural variants shape driver combinations and outcomes in pediatric high-grade glioma	27
Palbociclib demonstrates intracranial activity in progressive brain metastases harboring cyclin-dependent kinase pathway alterations	27
Small-molecule inhibitors that disrupt the MTDH–SND1 complex suppress breast cancer progression and metastasis	27
Chemotherapy induces canalization of cell state in childhood B-cell precursor acute lymphoblastic leukemia	27